SYBX

Synlogic, Inc. NASDAQ

Healthcare ·Biotechnology ·US · synlogictx.com

$0.60

Mkt Cap $7.0M

52w Low $0.54 3.9% of range 52w High $1.96

50d MA $0.63 200d MA $1.18

P/E (TTM) -7.6x

EV/EBITDA 0.2x

P/B 0.6x

Debt/Equity 0.0x

ROE -8.5%

P/FCF -3.2x

RSI (14) —

ATR (14) —

Beta 0.49

50d MA $0.63

200d MA $1.18

Avg Volume 12.1K

About

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353,…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 12, 2026	AMC	-0.09	0.12	+233.3%	0.60	+1.7%	+1.7%	+0.0%	+11.7%	+9.5%	+19.2%	—
Nov 13, 2025	AMC	-0.11	-0.19	-72.7%	1.67	+0.6%	+0.6%	+1.2%	-1.2%	-3.0%	-4.2%	—
Aug 7, 2025	AMC	-0.13	-0.04	+69.2%	1.36	-2.2%	+2.9%	+1.5%	+7.4%	+10.3%	+6.6%	—
Mar 6, 2025	AMC	-0.10	-0.06	+40.0%	1.31	+4.6%	+0.8%	-3.8%	-6.1%	-5.3%	-8.4%	—
Nov 12, 2024	AMC	-0.18	-0.01	+94.4%	1.46	-3.4%	-3.4%	-4.8%	-6.8%	-6.2%	-6.8%	—
Aug 8, 2024	AMC	-0.51	0.16	+131.4%	1.57	+4.5%	-7.0%	-10.8%	-12.7%	-10.2%	-9.6%	—
May 14, 2024	AMC	-0.80	-2.60	-225.0%	1.75	+0.0%	-1.7%	-4.0%	-5.7%	-7.4%	-5.7%	—
Mar 19, 2024	AMC	-1.11	-1.71	-54.1%	1.78	+0.0%	-2.8%	-1.7%	+1.1%	+1.1%	+0.0%	—
Nov 9, 2023	AMC	-2.55	-2.57	-0.8%	1.81	-0.6%	+2.2%	-0.6%	+17.1%	+16.0%	+9.9%	—
Aug 10, 2023	AMC	-3.90	-3.15	+19.2%	7.47	+0.0%	+2.4%	+2.5%	+6.7%	+5.6%	+1.1%	—
May 11, 2023	AMC	-3.75	-3.45	+8.0%	8.37	+0.2%	-0.4%	-1.4%	-3.3%	+1.1%	+2.5%	—
Mar 29, 2023	AMC	-3.90	-3.60	+7.7%	9.45	-3.1%	+6.3%	+0.3%	-7.9%	-14.9%	-20.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 20	HC Wainwright & Co.	Upgrade	Sell → Neutral	—	$1.78	$1.78	+0.0%	-2.8%	-1.7%	+1.1%	+1.1%	+0.0%
Feb 9	Leerink Partners	Downgrade	Outperform → Market Perform	—	$3.45	$1.61	-53.3%	-48.7%	-50.1%	-49.6%	-48.4%	-46.7%
Feb 9	HC Wainwright & Co.	Downgrade	Buy → Sell	—	$3.45	$1.61	-53.3%	-48.7%	-50.1%	-49.6%	-48.4%	-46.7%
Feb 9	Chardan Capital	Downgrade	Buy → Neutral	—	$3.45	$1.61	-53.3%	-48.7%	-50.1%	-49.6%	-48.4%	-46.7%
Aug 11	Chardan Capital	Maintains	Buy → Buy	—	$7.47	$7.47	+0.0%	+2.4%	+2.5%	+6.7%	+5.6%	+1.1%
Aug 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.47	$7.47	+0.0%	+2.4%	+2.5%	+6.7%	+5.6%	+1.1%
Aug 10	Chardan Capital	Maintains	Buy → Buy	—	$7.35	$7.39	+0.5%	+1.6%	+4.1%	+4.2%	+8.4%	+7.3%
Aug 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.35	$7.39	+0.5%	+1.6%	+4.1%	+4.2%	+8.4%	+7.3%
Jul 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.53	$7.92	+5.2%	+5.6%	-1.2%	+1.7%	+0.3%	-0.4%
Jul 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.84	$7.83	-0.1%	-4.0%	+1.4%	-5.1%	-2.3%	-3.7%
Jun 6	Chardan Capital	Maintains	Buy → Buy	—	$7.30	$7.99	+9.5%	+28.5%	+17.1%	+21.9%	+21.6%	+17.1%
Jun 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.30	$7.99	+9.5%	+28.5%	+17.1%	+21.9%	+21.6%	+17.1%
Jun 5	Chardan Capital	Maintains	Buy → Buy	—	$8.55	$8.40	-1.8%	-14.6%	+9.7%	+0.0%	+4.1%	+3.9%
Jun 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.55	$8.40	-1.8%	-14.6%	+9.7%	+0.0%	+4.1%	+3.9%
May 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.58	$8.70	+1.4%	-0.6%	-1.7%	-2.1%	-0.3%	-4.7%
May 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.46	$8.25	-2.5%	+1.4%	+0.8%	-0.4%	-0.7%	+1.1%
May 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.34	$8.85	+6.1%	-1.1%	-3.0%	+1.4%	+2.9%	+2.3%
May 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
Mar 30	Chardan Capital	Maintains	Buy → Buy	—	$9.45	$9.16	-3.1%	+6.3%	+0.3%	-7.9%	-14.9%	-20.5%
Mar 29	Chardan Capital	Maintains	Buy → Buy	—	$9.18	$9.47	+3.2%	+2.9%	+9.5%	+3.3%	-5.2%	-12.4%
Nov 11	Chardan Capital	Maintains	Buy → Buy	—	$9.65	$10.45	+8.3%	+15.0%	+13.4%	+16.4%	+11.0%	+0.5%
Nov 10	Chardan Capital	Maintains	Buy → Buy	—	$10.35	$11.25	+8.7%	-6.8%	+7.2%	+5.7%	+8.5%	+3.5%
Oct 18	Oppenheimer	Maintains	Outperform → Outperform	—	$16.20	$16.50	+1.9%	+0.0%	+0.9%	-0.9%	-1.9%	-12.0%
Oct 17	Oppenheimer	Maintains	Outperform → Outperform	—	$15.75	$16.35	+3.8%	+2.9%	+2.9%	+3.8%	+1.9%	+1.0%
May 13	Oppenheimer	Maintains	Outperform → Outperform	—	$16.05	$16.35	+1.9%	+8.4%	+1.9%	+8.4%	+2.8%	+13.1%
May 12	Oppenheimer	Maintains	Outperform → Outperform	—	$18.75	$19.20	+2.4%	-14.4%	-7.2%	-12.8%	-7.2%	-12.0%
Mar 18	SVB Leerink	Maintains	Outperform → Outperform	—	$30.60	$30.60	+0.0%	+9.3%	+9.3%	+20.1%	+20.6%	+23.5%
Mar 17	SVB Leerink	Maintains	Outperform → Outperform	—	$32.10	$32.10	+0.0%	-4.7%	+4.2%	+4.2%	+14.5%	+15.0%
Nov 24	Oppenheimer	Upgrade	Perform → Outperform	—	$36.00	$38.76	+7.7%	+10.0%	+7.9%	+0.8%	+3.8%	+0.8%
Nov 23	Oppenheimer	Upgrade	Perform → Outperform	—	$37.05	$37.80	+2.0%	-2.8%	+6.9%	+4.9%	-2.0%	+0.8%
Nov 11	SVB Leerink	Maintains	Outperform → Outperform	—	$39.90	$39.45	-1.1%	-0.4%	+3.8%	+3.8%	+3.4%	+0.8%
Nov 10	SVB Leerink	Maintains	Outperform → Outperform	—	$40.35	$44.10	+9.3%	-1.1%	-1.5%	+2.6%	+2.6%	+2.2%
Oct 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$41.25	$41.70	+1.1%	+0.0%	-2.2%	-1.8%	-5.8%	-5.8%
Oct 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.95	$40.80	-0.4%	+0.7%	+0.7%	-1.5%	-1.1%	-5.1%
Sep 20	Piper Sandler	Maintains	Overweight → Overweight	—	$49.35	$52.80	+7.0%	+12.8%	+8.5%	+6.1%	-3.3%	-3.6%
Sep 19	Piper Sandler	Maintains	Overweight → Overweight	—	—	—	—	—	—	—	—	—
Jun 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$63.00	$63.90	+1.4%	-1.4%	-4.5%	-7.4%	-2.4%	-7.4%
Jun 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
Mar 18	JonesTrading	Maintains	Buy → Buy	—	$62.70	$67.17	+7.1%	-3.8%	+6.9%	+4.8%	-1.4%	-7.2%
Jan 13	Chardan Capital	Maintains	Buy → Buy	—	$36.00	$44.85	+24.6%	+32.5%	+35.8%	+46.7%	+58.8%	+60.0%
Jan 12	Chardan Capital	Maintains	Buy → Buy	—	$36.15	$36.45	+0.8%	-0.4%	+32.0%	+35.3%	+46.1%	+58.1%
Aug 21	Oppenheimer	Downgrade	Outperform → Perform	—	$52.35	$47.85	-8.6%	-7.4%	-10.3%	-6.3%	-7.7%	-7.2%
Aug 21	Citigroup	Downgrade	Buy → Sell	—	$52.35	$47.85	-8.6%	-7.4%	-10.3%	-6.3%	-7.7%	-7.2%
Aug 20	Oppenheimer	Downgrade	Outperform → Perform	—	$72.45	$50.55	-30.2%	-27.7%	-33.1%	-35.2%	-32.3%	-33.3%
Aug 20	Citigroup	Downgrade	Buy → Sell	—	$72.45	$50.55	-30.2%	-27.7%	-33.1%	-35.2%	-32.3%	-33.3%
Apr 30	Jefferies	Maintains	Buy → Buy	—	$116.10	$120.60	+3.9%	+10.9%	+12.9%	+3.7%	+13.0%	+12.1%
Feb 13	BTIG Research	Maintains	Buy → Buy	—	$143.40	$144.75	+0.9%	+7.1%	-6.4%	-2.8%	-2.7%	-0.6%
Dec 13	Chardan Capital	Maintains	Buy → Buy	—	$114.60	$116.85	+2.0%	-1.3%	+0.0%	-2.7%	-7.7%	-12.7%
Aug 24	Citigroup	Upgrade	Neutral → Buy	—	$117.90	$127.50	+8.1%	+15.1%	+17.9%	+21.6%	+22.0%	+27.4%
Aug 23	Citigroup	Upgrade	Neutral → Buy	—	$118.65	$118.35	-0.3%	-0.6%	+14.4%	+17.2%	+20.9%	+21.2%

Data updated apr 28, 2026 10:18pm · Source: massive.com